[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "Transcather vs Surgical Aortic Valve Replacement in Young Adults with Chronic Kidney Disease",
    "section": "",
    "text": "Study Objective: Examine in-hospital outcomes in young adults with CKD undergoing TAVR or SAVR.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPopulation: Included inpatient admissions (age&lt;65) with CKD undergoing aortic valve replacement.\nPrimary Outcomes:\n\nIn-hospital mortality\nTotal hospital charges\nLength of stay\n\nSecondary Outcomes:\n\nCardiogenic shock\nCardiac arrest\nMajor bleeding\nVenous thromboembolism\nAcute kidney injury\nAcute myocardial infarction\n\nStatistical Analysis: Descriptive statistics for variables of interest are present as frequency and percentage of total admissions. Comparative statistics between patient groups was performed. Multiple logistic and linear regression was performed to identify variables independently associated with outcomes in young adults undergoing aortic valve replacement, respectively, adjusted for:\n\nDemographics: Age, sex, race, residential income, insurance\nHospital Characteristics: hospital region, and hospital bedsize\nComorbidities (identified based on clinical relevance and literature review) and CKD stage\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "Transcather vs Surgical Aortic Valve Replacement in Young Adults with Chronic Kidney Disease",
    "section": "",
    "text": "Study Objective: Examine in-hospital outcomes in young adults with CKD undergoing TAVR or SAVR.\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPopulation: Included inpatient admissions (age&lt;65) with CKD undergoing aortic valve replacement.\nPrimary Outcomes:\n\nIn-hospital mortality\nTotal hospital charges\nLength of stay\n\nSecondary Outcomes:\n\nCardiogenic shock\nCardiac arrest\nMajor bleeding\nVenous thromboembolism\nAcute kidney injury\nAcute myocardial infarction\n\nStatistical Analysis: Descriptive statistics for variables of interest are present as frequency and percentage of total admissions. Comparative statistics between patient groups was performed. Multiple logistic and linear regression was performed to identify variables independently associated with outcomes in young adults undergoing aortic valve replacement, respectively, adjusted for:\n\nDemographics: Age, sex, race, residential income, insurance\nHospital Characteristics: hospital region, and hospital bedsize\nComorbidities (identified based on clinical relevance and literature review) and CKD stage\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#descriptive-analysis",
    "href": "quarto/index.html#descriptive-analysis",
    "title": "Transcather vs Surgical Aortic Valve Replacement in Young Adults with Chronic Kidney Disease",
    "section": "Descriptive analysis",
    "text": "Descriptive analysis\n\nBaseline Characteristics:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall\nN = 11,3151\nSAVR\nN = 7,4501\nTAVR\nN = 3,8651\np-value2\n\n\n\n\nAge, y\n59 (54, 62)\n58 (52, 62)\n61 (57, 63)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n&lt;0.001\n\n\n    Female\n3,225 (29%)\n1,880 (25%)\n1,345 (35%)\n\n\n\n\n    Male\n8,090 (71%)\n5,570 (75%)\n2,520 (65%)\n\n\n\n\nResidential income\n\n\n\n\n\n\n0.029\n\n\n    $1 - $51,999\n3,330 (30%)\n2,105 (29%)\n1,225 (32%)\n\n\n\n\n    $52,000 - $65,999\n3,210 (29%)\n2,125 (29%)\n1,085 (29%)\n\n\n\n\n    $66,000 - $87,999\n2,550 (23%)\n1,640 (22%)\n910 (24%)\n\n\n\n\n    $88,000 or more\n1,990 (18%)\n1,435 (20%)\n555 (15%)\n\n\n\n\nExpected primary payer\n\n\n\n\n\n\n&lt;0.001\n\n\n    Private\n4,945 (44%)\n3,860 (52%)\n1,085 (28%)\n\n\n\n\n    Medicaid\n1,745 (15%)\n1,205 (16%)\n540 (14%)\n\n\n\n\n    Medicare\n4,200 (37%)\n2,105 (28%)\n2,095 (54%)\n\n\n\n\n    Other\n405 (3.6%)\n260 (3.5%)\n145 (3.8%)\n\n\n\n\nHospital region\n\n\n\n\n\n\n0.2\n\n\n    Midwest\n2,915 (26%)\n2,015 (27%)\n900 (23%)\n\n\n\n\n    Northeast\n1,955 (17%)\n1,215 (16%)\n740 (19%)\n\n\n\n\n    South\n4,275 (38%)\n2,775 (37%)\n1,500 (39%)\n\n\n\n\n    West\n2,170 (19%)\n1,445 (19%)\n725 (19%)\n\n\n\n\nHospital bedsize\n\n\n\n\n\n\n0.058\n\n\n    Large\n8,295 (73%)\n5,345 (72%)\n2,950 (76%)\n\n\n\n\n    Medium\n2,225 (20%)\n1,525 (20%)\n700 (18%)\n\n\n\n\n    Small\n795 (7.0%)\n580 (7.8%)\n215 (5.6%)\n\n\n\n\nCKD stage\n\n\n\n\n\n\n&lt;0.001\n\n\n    CKD, stage 1-3\n4,925 (88%)\n3,710 (91%)\n1,215 (80%)\n\n\n\n\n    CKD, stage 4-5\n670 (12%)\n375 (9.2%)\n295 (20%)\n\n\n\n\nHypertension\n10,305 (91%)\n6,690 (90%)\n3,615 (94%)\n0.003\n\n\nDiabetes mellitus\n5,465 (48%)\n3,180 (43%)\n2,285 (59%)\n&lt;0.001\n\n\nCoronary artery disease\n5,990 (53%)\n3,585 (48%)\n2,405 (62%)\n&lt;0.001\n\n\nHeart failure\n8,130 (72%)\n4,915 (66%)\n3,215 (83%)\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n2,775 (25%)\n1,695 (23%)\n1,080 (28%)\n0.005\n\n\nLiver disease\n1,300 (11%)\n720 (9.7%)\n580 (15%)\n&lt;0.001\n\n\nAtrial Fibrillation\n3,705 (33%)\n2,690 (36%)\n1,015 (26%)\n&lt;0.001\n\n\nObesity\n3,695 (33%)\n2,410 (32%)\n1,285 (33%)\n0.7\n\n\nTobacco use disorder\n80 (0.7%)\n60 (0.8%)\n20 (0.5%)\n0.4\n\n\nPrior stroke\n1,275 (11%)\n685 (9.2%)\n590 (15%)\n&lt;0.001\n\n\nPrior coronary artery bypass graft\n745 (6.6%)\n260 (3.5%)\n485 (13%)\n&lt;0.001\n\n\nPrior myocardial infarction\n1,165 (10%)\n580 (7.8%)\n585 (15%)\n&lt;0.001\n\n\nCharlson comorbidity index\n5.00 (4.00, 6.00)\n4.00 (3.00, 5.00)\n5.00 (4.00, 6.00)\n&lt;0.001\n\n\n\n1 Median (Q1, Q3); n (%)\n\n\n2 Design-based KruskalWallis test; Pearson’s X^2: Rao & Scott adjustment\n\n\n\n\n\n\n\n\n\n\nOutcomes Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall\nN = 11,3151\nSAVR\nN = 7,4501\nTAVR\nN = 3,8651\np-value2\n\n\n\n\nDied during hospitalization\n400 (3.5%)\n335 (4.5%)\n65 (1.7%)\n&lt;0.001\n\n\nLength of stay (days)\n8 (4, 14)\n10 (6, 17)\n3 (1, 8)\n&lt;0.001\n\n\nInflation-adjusted total charge ($)\n235,534 (164,420, 382,600)\n259,123 (173,371, 425,177)\n207,507 (151,560, 306,436)\n&lt;0.001\n\n\nMajor bleeding\n1,065 (9.4%)\n700 (9.4%)\n365 (9.4%)\n&gt;0.9\n\n\nAcute ischemic stroke\n705 (6.2%)\n460 (6.2%)\n245 (6.3%)\n0.9\n\n\nCardiogenic shock\n1,225 (11%)\n960 (13%)\n265 (6.9%)\n&lt;0.001\n\n\nCardiac arrest\n270 (2.4%)\n215 (2.9%)\n55 (1.4%)\n0.028\n\n\nAcute kidney injury\n4,180 (37%)\n3,405 (46%)\n775 (20%)\n&lt;0.001\n\n\nVenous thromboembolism\n500 (4.4%)\n425 (5.7%)\n75 (1.9%)\n&lt;0.001\n\n\nAcute myocardial infarction\n940 (8.3%)\n720 (9.7%)\n220 (5.7%)\n0.001\n\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s X^2: Rao & Scott adjustment; Design-based KruskalWallis test"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "Transcather vs Surgical Aortic Valve Replacement in Young Adults with Chronic Kidney Disease",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nIn-hospital mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nAVR\n\n\n\n\n\n\n\n\n    SAVR\n—\n—\n\n\n\n\n    TAVR\n0.45\n0.19, 1.08\n0.074\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n0.97\n0.43, 2.17\n&gt;0.9\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Black\n0.66\n0.24, 1.82\n0.4\n\n\n    Hispanic\n1.16\n0.32, 4.14\n0.8\n\n\n    Other\n1.49\n0.31, 7.04\n0.6\n\n\nAge, y\n1.05\n0.98, 1.13\n0.2\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.65\n0.27, 1.61\n0.4\n\n\n    $66,000 - $87,999\n0.34\n0.09, 1.29\n0.11\n\n\n    $88,000 or more\n1.19\n0.42, 3.40\n0.7\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.93\n0.29, 3.02\n&gt;0.9\n\n\n    Medicare\n1.57\n0.67, 3.70\n0.3\n\n\n    Other\n1.09\n0.12, 9.43\n&gt;0.9\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.45\n0.11, 1.85\n0.3\n\n\n    South\n2.09\n0.93, 4.70\n0.074\n\n\n    West\n0.56\n0.13, 2.53\n0.5\n\n\nHospital bedsize\n\n\n\n\n\n\n\n\n    Large\n—\n—\n\n\n\n\n    Medium\n1.50\n0.67, 3.34\n0.3\n\n\n    Small\n0.29\n0.04, 2.32\n0.2\n\n\nCKD stage\n\n\n\n\n\n\n\n\n    CKD, stage 1-3\n—\n—\n\n\n\n\n    CKD, stage 4-5\n2.28\n1.03, 5.04\n0.043\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n3.36\n1.13, 10.0\n0.030\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.34\n0.34, 16.1\n0.4\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.85\n0.41, 1.74\n0.7\n\n\nAtrial Fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.42\n0.18, 1.00\n0.051\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nMajor bleeding:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nAVR\n\n\n\n\n\n\n\n\n    SAVR\n—\n—\n\n\n\n\n    TAVR\n1.26\n0.76, 2.07\n0.4\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.13\n0.69, 1.84\n0.6\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Black\n0.76\n0.39, 1.49\n0.4\n\n\n    Hispanic\n1.08\n0.47, 2.45\n0.9\n\n\n    Other\n1.25\n0.44, 3.53\n0.7\n\n\nAge, y\n0.99\n0.96, 1.03\n0.7\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.90\n0.50, 1.64\n0.7\n\n\n    $66,000 - $87,999\n1.25\n0.68, 2.32\n0.5\n\n\n    $88,000 or more\n0.96\n0.47, 1.96\n&gt;0.9\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n1.65\n0.90, 3.05\n0.11\n\n\n    Medicare\n2.00\n1.18, 3.39\n0.010\n\n\n    Other\n0.73\n0.16, 3.25\n0.7\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.74\n0.37, 1.49\n0.4\n\n\n    South\n1.22\n0.71, 2.10\n0.5\n\n\n    West\n0.89\n0.43, 1.85\n0.8\n\n\nHospital bedsize\n\n\n\n\n\n\n\n\n    Large\n—\n—\n\n\n\n\n    Medium\n1.17\n0.66, 2.09\n0.6\n\n\n    Small\n1.44\n0.66, 3.12\n0.4\n\n\nCKD stage\n\n\n\n\n\n\n\n\n    CKD, stage 1-3\n—\n—\n\n\n\n\n    CKD, stage 4-5\n1.24\n0.67, 2.29\n0.5\n\n\nAtrial Fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.95\n0.59, 1.55\n0.8\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.93\n0.58, 1.49\n0.8\n\n\nPrior coronary artery bypass graft\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.23\n0.51, 2.96\n0.6\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n4.02\n2.39, 6.78\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.56\n0.29, 1.09\n0.086\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nAcute ischemic stroke:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nAVR\n\n\n\n\n\n\n\n\n    SAVR\n—\n—\n\n\n\n\n    TAVR\n1.04\n0.52, 2.08\n&gt;0.9\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n2.83\n1.25, 6.41\n0.013\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Black\n1.01\n0.48, 2.10\n&gt;0.9\n\n\n    Hispanic\n0.43\n0.12, 1.62\n0.2\n\n\n    Other\n0.29\n0.03, 2.50\n0.3\n\n\nAge, y\n0.96\n0.93, 1.0\n0.026\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n1.05\n0.50, 2.21\n&gt;0.9\n\n\n    $66,000 - $87,999\n1.02\n0.44, 2.36\n&gt;0.9\n\n\n    $88,000 or more\n0.72\n0.28, 1.82\n0.5\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n1.82\n0.82, 4.03\n0.14\n\n\n    Medicare\n1.69\n0.82, 3.48\n0.2\n\n\n    Other\n1.45\n0.30, 6.93\n0.6\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.81\n0.32, 2.04\n0.7\n\n\n    South\n1.35\n0.62, 2.93\n0.5\n\n\n    West\n2.14\n0.91, 5.00\n0.080\n\n\nCKD stage\n\n\n\n\n\n\n\n\n    CKD, stage 1-3\n—\n—\n\n\n\n\n    CKD, stage 4-5\n1.18\n0.51, 2.73\n0.7\n\n\nAtrial Fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.77\n0.41, 1.45\n0.4\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.48\n0.42, 5.16\n0.5\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.42\n0.77, 2.62\n0.3\n\n\nPrior stroke\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.32\n0.07, 1.36\n0.12\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.48\n1.03, 5.97\n0.043\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.25\n0.67, 2.33\n0.5\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nAcute kidney injury:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nAVR\n\n\n\n\n\n\n\n\n    SAVR\n—\n—\n\n\n\n\n    TAVR\n0.30\n0.21, 0.42\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.19\n0.88, 1.60\n0.3\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Black\n1.07\n0.74, 1.55\n0.7\n\n\n    Hispanic\n1.34\n0.80, 2.25\n0.3\n\n\n    Other\n0.56\n0.31, 1.02\n0.057\n\n\nAge, y\n0.98\n0.96, 1.00\n0.076\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n1.22\n0.85, 1.75\n0.3\n\n\n    $66,000 - $87,999\n0.95\n0.65, 1.39\n0.8\n\n\n    $88,000 or more\n1.18\n0.76, 1.81\n0.5\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.95\n0.64, 1.41\n0.8\n\n\n    Medicare\n1.24\n0.89, 1.72\n0.2\n\n\n    Other\n0.65\n0.30, 1.40\n0.3\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.75\n0.50, 1.14\n0.2\n\n\n    South\n0.99\n0.70, 1.40\n&gt;0.9\n\n\n    West\n1.01\n0.64, 1.59\n&gt;0.9\n\n\nCKD stage\n\n\n\n\n\n\n\n\n    CKD, stage 1-3\n—\n—\n\n\n\n\n    CKD, stage 4-5\n3.72\n2.37, 5.85\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.33\n1.01, 1.74\n0.043\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.40\n0.89, 2.20\n0.14\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.55\n1.88, 3.46\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.05\n0.80, 1.37\n0.7\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nCardiogenic shock:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nAVR\n\n\n\n\n\n\n\n\n    SAVR\n—\n—\n\n\n\n\n    TAVR\n0.54\n0.31, 0.94\n0.029\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n0.99\n0.62, 1.58\n&gt;0.9\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Black\n1.20\n0.68, 2.11\n0.5\n\n\n    Hispanic\n1.09\n0.49, 2.45\n0.8\n\n\n    Other\n0.35\n0.08, 1.50\n0.2\n\n\nAge, y\n0.99\n0.96, 1.02\n0.5\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.53\n0.31, 0.93\n0.027\n\n\n    $66,000 - $87,999\n0.70\n0.39, 1.28\n0.2\n\n\n    $88,000 or more\n0.72\n0.37, 1.40\n0.3\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n1.09\n0.62, 1.90\n0.8\n\n\n    Medicare\n0.77\n0.45, 1.31\n0.3\n\n\n    Other\n0.24\n0.03, 1.75\n0.2\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.40\n0.19, 0.86\n0.019\n\n\n    South\n0.82\n0.49, 1.37\n0.4\n\n\n    West\n0.77\n0.39, 1.51\n0.4\n\n\nCKD stage\n\n\n\n\n\n\n\n\n    CKD, stage 1-3\n—\n—\n\n\n\n\n    CKD, stage 4-5\n1.44\n0.83, 2.50\n0.2\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n14.1\n4.92, 40.6\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.01\n0.65, 1.59\n&gt;0.9\n\n\nPrior myocardial infarction\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.82\n0.39, 1.74\n0.6\n\n\nAtrial Fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.96\n0.63, 1.47\n0.8\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.86\n0.57, 1.31\n0.5\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nCardiac arrest:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nAVR\n\n\n\n\n\n\n\n\n    SAVR\n—\n—\n\n\n\n\n    TAVR\n0.16\n0.02, 1.34\n0.090\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.52\n0.40, 5.69\n0.5\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Black\n0.86\n0.25, 2.99\n0.8\n\n\n    Hispanic\n1.59\n0.33, 7.61\n0.6\n\n\n    Other\n0.00\n0.00, 0.00\n&lt;0.001\n\n\nAge, y\n1.00\n0.93, 1.07\n&gt;0.9\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n1.68\n0.38, 7.37\n0.5\n\n\n    $66,000 - $87,999\n2.38\n0.53, 10.6\n0.3\n\n\n    $88,000 or more\n2.36\n0.56, 10.0\n0.2\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.47\n0.06, 3.62\n0.5\n\n\n    Medicare\n1.29\n0.35, 4.72\n0.7\n\n\n    Other\n3.50\n0.68, 18.1\n0.14\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n1.54\n0.32, 7.45\n0.6\n\n\n    South\n3.15\n0.86, 11.5\n0.084\n\n\n    West\n0.53\n0.05, 5.95\n0.6\n\n\nCKD stage\n\n\n\n\n\n\n\n\n    CKD, stage 1-3\n—\n—\n\n\n\n\n    CKD, stage 4-5\n1.48\n0.32, 6.84\n0.6\n\n\nCharlson comorbidity index\n1.10\n0.85, 1.43\n0.5\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nVenous thromboembolism:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nAVR\n\n\n\n\n\n\n\n\n    SAVR\n—\n—\n\n\n\n\n    TAVR\n0.32\n0.10, 0.97\n0.045\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.05\n0.49, 2.26\n&gt;0.9\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Black\n0.95\n0.42, 2.19\n&gt;0.9\n\n\n    Hispanic\n0.71\n0.20, 2.49\n0.6\n\n\n    Other\n0.00\n0.00, 0.00\n&lt;0.001\n\n\nAge, y\n0.96\n0.93, 1.0\n0.025\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.38\n0.15, 0.97\n0.044\n\n\n    $66,000 - $87,999\n0.68\n0.27, 1.70\n0.4\n\n\n    $88,000 or more\n0.62\n0.23, 1.64\n0.3\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n1.21\n0.49, 2.99\n0.7\n\n\n    Medicare\n0.87\n0.33, 2.35\n0.8\n\n\n    Other\n2.53\n0.67, 9.56\n0.2\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.60\n0.21, 1.73\n0.3\n\n\n    South\n0.55\n0.24, 1.24\n0.15\n\n\n    West\n0.84\n0.29, 2.40\n0.7\n\n\nCKD stage\n\n\n\n\n\n\n\n\n    CKD, stage 1-3\n—\n—\n\n\n\n\n    CKD, stage 4-5\n1.22\n0.44, 3.39\n0.7\n\n\nObesity\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.55\n0.26, 1.17\n0.12\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.50\n0.68, 3.31\n0.3\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.97\n0.47, 2.00\n&gt;0.9\n\n\nAtrial Fibrillation\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.36\n0.68, 2.69\n0.4\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.68\n0.33, 1.41\n0.3\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio\n\n\n\n\n\n\n\n\n\n\nAcute myocardial infarction:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR\n95% CI\np-value\n\n\n\n\nAVR\n\n\n\n\n\n\n\n\n    SAVR\n—\n—\n\n\n\n\n    TAVR\n0.55\n0.29, 1.01\n0.055\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.27\n0.73, 2.21\n0.4\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Black\n0.87\n0.45, 1.66\n0.7\n\n\n    Hispanic\n0.54\n0.21, 1.39\n0.2\n\n\n    Other\n0.41\n0.09, 1.78\n0.2\n\n\nAge, y\n1.03\n0.98, 1.08\n0.3\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n1.02\n0.56, 1.85\n&gt;0.9\n\n\n    $66,000 - $87,999\n1.05\n0.56, 1.95\n0.9\n\n\n    $88,000 or more\n0.84\n0.42, 1.68\n0.6\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n1.00\n0.50, 2.03\n&gt;0.9\n\n\n    Medicare\n0.69\n0.36, 1.29\n0.2\n\n\n    Other\n0.34\n0.04, 2.72\n0.3\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.91\n0.43, 1.94\n0.8\n\n\n    South\n1.60\n0.90, 2.84\n0.11\n\n\n    West\n1.73\n0.84, 3.58\n0.14\n\n\nCKD stage\n\n\n\n\n\n\n\n\n    CKD, stage 1-3\n—\n—\n\n\n\n\n    CKD, stage 4-5\n1.51\n0.77, 2.96\n0.2\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.50\n1.47, 4.24\n&lt;0.001\n\n\nPrior myocardial infarction\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.87\n0.37, 2.04\n0.7\n\n\nPrior coronary artery bypass graft\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.13\n0.02, 1.07\n0.057\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.93\n1.18, 3.16\n0.009\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.04\n0.60, 6.91\n0.2\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n3.13\n1.59, 6.17\n0.001\n\n\n\nAbbreviations: CI = Confidence Interval, OR = Odds Ratio"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "Transcather vs Surgical Aortic Valve Replacement in Young Adults with Chronic Kidney Disease",
    "section": "Multivariable Linear Regression:",
    "text": "Multivariable Linear Regression:\n\nLength of stay:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI\np-value\n\n\n\n\nAVR\n\n\n\n\n\n\n\n\n    SAVR\n—\n—\n\n\n\n\n    TAVR\n-6.9\n-8.3, -5.4\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n-0.60\n-2.0, 0.85\n0.4\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Black\n2.8\n0.36, 5.2\n0.024\n\n\n    Hispanic\n1.8\n-1.0, 4.7\n0.2\n\n\n    Other\n0.19\n-3.2, 3.5\n&gt;0.9\n\n\nAge, y\n-0.04\n-0.17, 0.08\n0.5\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n-1.4\n-3.1, 0.25\n0.095\n\n\n    $66,000 - $87,999\n-0.99\n-2.8, 0.77\n0.3\n\n\n    $88,000 or more\n-0.26\n-2.9, 2.4\n0.8\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n3.0\n0.79, 5.2\n0.008\n\n\n    Medicare\n1.5\n0.04, 2.9\n0.044\n\n\n    Other\n1.9\n-2.0, 5.7\n0.3\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n-1.1\n-2.9, 0.67\n0.2\n\n\n    South\n0.60\n-1.1, 2.3\n0.5\n\n\n    West\n-1.7\n-3.4, 0.01\n0.052\n\n\nCKD stage\n\n\n\n\n\n\n\n\n    CKD, stage 1-3\n—\n—\n\n\n\n\n    CKD, stage 4-5\n3.9\n1.3, 6.6\n0.003\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n4.3\n3.0, 5.5\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.47\n-1.8, 0.86\n0.5\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.62\n-0.97, 2.2\n0.4\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1.9\n-4.1, 0.35\n0.10\n\n\n\nAbbreviation: CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nTotal hospital charges:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI\np-value\n\n\n\n\nAVR\n\n\n\n\n\n\n\n\n    SAVR\n—\n—\n\n\n\n\n    TAVR\n-62,182\n-98,141, -26,224\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n810\n-33,016, 34,635\n&gt;0.9\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Black\n62,770\n1,335, 124,205\n0.045\n\n\n    Hispanic\n46,097\n-21,346, 113,539\n0.2\n\n\n    Other\n54,944\n-59,061, 168,948\n0.3\n\n\nAge, y\n-2,204\n-5,467, 1,060\n0.2\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n-18,810\n-56,372, 18,752\n0.3\n\n\n    $66,000 - $87,999\n-11,660\n-52,213, 28,892\n0.6\n\n\n    $88,000 or more\n49,637\n-18,620, 117,893\n0.2\n\n\nExpected primary payer\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n52,434\n2,323, 102,545\n0.040\n\n\n    Medicare\n25,885\n-8,330, 60,100\n0.14\n\n\n    Other\n-744\n-79,363, 77,875\n&gt;0.9\n\n\nHospital region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n12,692\n-25,816, 51,201\n0.5\n\n\n    South\n64,295\n26,082, 102,508\n0.001\n\n\n    West\n107,731\n41,364, 174,099\n0.002\n\n\nCKD stage\n\n\n\n\n\n\n\n\n    CKD, stage 1-3\n—\n—\n\n\n\n\n    CKD, stage 4-5\n57,430\n1,871, 112,989\n0.043\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n91,990\n65,219, 118,762\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1,088\n-30,001, 32,177\n&gt;0.9\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2,678\n-38,766, 44,122\n0.9\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-46,496\n-104,085, 11,093\n0.11\n\n\n\nAbbreviation: CI = Confidence Interval"
  }
]